Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer

By LabMedica International staff writers
Posted on 26 Dec 2025

Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. More...

Treatment is particularly challenging because the tumor infiltrates brain tissue and most chemotherapy drugs cannot cross the blood–brain barrier, leaving residual cancer cells behind after surgery. Even when advanced techniques are used to deliver drugs into the brain, doctors often must wait months to determine whether a therapy is effective. Now, new research shows that blood samples can reveal whether chemotherapy is working in glioblastoma after ultrasound-assisted opening of the blood–brain barrier.

The work, led by Northwestern Medicine (Chicago, IL, USA) in collaboration with the University of Michigan (Ann Arbor, MI, USA), builds on an earlier clinical trial in which a therapeutic ultrasound device temporarily opened the blood–brain barrier, allowing the chemotherapy drug paclitaxel to reach glioblastoma tumors. The new approach examines what happens next, specifically whether tumor-derived material released into the bloodstream can be used to monitor treatment response.

The team analyzed tiny particles known as extracellular vesicles and particles (EVPs), which are released by cancer cells and carry tumor-specific genetic material and proteins. By using a microfluidic diagnostic platform called the GlioExoChip, researchers selectively isolated EVPs originating from glioblastoma cells based on a lipid signature found on their surface. This turns routine blood samples into a form of liquid biopsy capable of tracking tumor behavior over time.

The researchers demonstrated that opening the blood–brain barrier not only allows chemotherapy to enter the brain but also permits tumor-derived EVPs to leak into the bloodstream. Blood samples taken before and after each chemotherapy session showed measurable changes in EVP levels that correlated with treatment response. The findings, published in Nature Communications, show that when the ratio of post-treatment to pre-treatment EVPs increased over successive sessions, chemotherapy was effective; when the ratio remained flat or declined, treatment was unsuccessful.

This blood-based monitoring approach could allow clinicians to determine after a single chemotherapy dose whether a treatment is working, rather than waiting months for imaging results that can be misleading. It may help doctors decide whether to continue, change, or stop chemotherapy earlier, sparing patients from unnecessary side effects. The researchers plan to validate the method with additional glioblastoma therapies and explore whether EVP-based liquid biopsies can be applied to other cancers treated with blood–brain barrier–opening techniques.

"Instead of waiting months, after one dose we can know if a given treatment is working," said Northwestern Medicine neurosurgeon Adam Sonaband, co-corresponding author of the study. "That is huge for glioblastoma patients. It could potentially prevent patients from getting prolonged treatments that are ineffective, thus also avoiding unnecessary side effects."

Related Links:
Northwestern Medicine
University of Michigan 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.